Dendritic cell vaccines for the immunocompromised patient: Prevention of influenza virus infection

Expert Review of Vaccines

Volumn 9, Issue 7, 2010, Pages 721-730

  Decker, William K ^a   Safdar, Amar ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

B cell malignancy; dendritic cell; influenza; vaccination

Indexed keywords

COLONY STIMULATING FACTOR 1; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HAEMOPHILUS INFLUENZAE VACCINE; HEPATITIS B VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; INTERLEUKIN 10; INTERLEUKIN 6; MUCIN 1; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; PROSTATE SPECIFIC ANTIGEN; VARICELLA ZOSTER VACCINE; VASCULOTROPIN;

ADOPTIVE IMMUNOTHERAPY; ANTIBODY RESPONSE; ANTIBODY TITER; CANCER PATIENT; CELL DIFFERENTIATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DENDRITIC CELL; GRAFT RECIPIENT; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE TYPE B; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HERPES ZOSTER; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS; PNEUMOCOCCAL INFECTION; POLIOMYELITIS; PRIORITY JOURNAL; REVIEW;

ANTIGENS, VIRAL; BIOMEDICAL RESEARCH; DENDRITIC CELLS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOTHERAPY; INFLUENZA VACCINES; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE;

EID: 77954669798     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.68     Document Type: Review

References (108)

1. Sommer AL, Wachel BK, Smith JA. Evaluation of vaccine dosing in patients with solid tumors receiving myelosuppressive chemotherapy. J. Oncol. Pharm. Pract. 12(3), 143-154 (2006).
2. Cohen JI. Strategies for herpes zoster vaccination of immunocompromised patients. J. Infect. Dis. 197(Suppl. 2), S237-S241 (2008).
3. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect. Dis. 9(8), 493-504 (2009).
4. 4+CD25 + regulatory T cell-mediated immunosuppression. Cytokine Growth Factor Rev. 14(2), 85-89 (2003).
5. Humphries W, Wei J, Sampson JH, Heimberger AB. The role of tregs in glioma-mediated immunosuppression: potential target for intervention. Neurosurg. Clin. N. Am. 21(1), 125-137 (2010).
6. Kirkbride KC, Blobe GC. Inhibiting the TGF-p signalling pathway as a means of cancer immunotherapy. Expert. Opin. Biol. Ther. 3(2), 251-261 (2003).
7. Li MO, Flavell RA. TGF-p: a master of all T cell trades. Cell 134(3), 392-404 (2008).
8. Nagaraj S, Gabrilovich DI. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res. 68 (8), 2561-2563 (2008).
9. Pan PY, Ma G, Weber KJ et al. Immune stimulatory receptor CD40 is required for t-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res. DOI: 10.1158/0008-5472.CAN-09-1882 (2009) (Epub ahead of print).
10. Allavena P, Piemonti L, Longoni D et al. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur. J. Immunol. 28(1), 359-369 (1998).
11. Beckebaum S, Zhang X, Chen X et al. Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. Clin. Cancer Res. 10(21), 7260-7269 (2004).
12. Buelens C, Verhasselt V, De Groote D, Thielemans K, Goldman M, Willems F. Interleukin-10 prevents the generation of dendritic cells from human peripheral blood mononuclear cells cultured with interleukin-4 and granulocyte/ macrophage-colony-stimulating factor. Eur. J. Immunol. 27(3), 756-762 (1997).
13. Enk AH, Angeloni VL, Udey MC, Katz SI. Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance. J. Immunol. 151(5), 2390-2398 (1993).
14. Ludewig B, Graf D, Gelderblom HR, Becker Y, Kroczek RA, Pauli G. Spontaneous apoptosis of dendritic cells is efficiently inhibited by TRAP (CD40-ligand) and TNF-a, but strongly enhanced by interleukin-10. Eur. J. Immunol. 25(7), 1943-1950 (1995).
15. Menetrier-Caux C, Montmain G, Dieu MC et al. Inhibition of the differentiation of dendritic cells from CD34+ progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 92(12), 4778-4791 (1998).
16. Park SJ, Nakagawa T, Kitamura H et al. IL- 6 regulates in vivo dendritic cell differentiation through STAT3 activation. J. Immunol. 173(6), 3844-3854 (2004).
17. Pinzon-Charry A, Maxwell T, Lopez JA. Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol. Cell Biol. 83(5), 451-461 (2005).
18. Ratta M, Fagnoni F, Curti A et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 100(1), 230-237 (2002).
19. Cohen N, Mouly E, Hamdi H et al. GILZ expression in human dendritic cells redirects their maturation and prevents antigen-specific T lymphocyte response. Blood 107(5), 2037-2044 (2006).
20. Gabrilovich D, Ishida T, Oyama T et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92(11), 4150-4166 (1998).
21. Gottfried E, Kreutz M, Mackensen A. Tumor-induced modulation of dendritic cell function. Cytokine Growth Factor Rev. 19(1), 65-77 (2008).
22. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8 + T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 172(2), 989-999 (2004).
23. Lissoni P, Malugani F, Bonfanti A et al. Abnormally enhanced blood concentrations of vascular endothelial growth factor ( VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1. J. Biol. Regul. Homeost. Agents 15(2), 140-144 (2001).
24. Pak AS, Wright MA, Matthews JP, Collins SL, Petruzzelli GJ, Young MR. Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34+ cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin. Cancer Res. 1(1), 95-103 (1995).
25. Saito H, Tsujitani S, Ikeguchi M, Maeta M, Kaibara N. Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. Br. J. Cancer 78(12), 1573-1577 (1998).
26. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 64(17), 6337-6343 (2004).
27. Takahashi A, Kono K, Ichihara F, Sugai H, Fujii H, Matsumoto Y. Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines. Cancer Immunol. Immunother. 53(6), 543-550 (2004).
28. Young MR, Wright MA, Lozano Y et al. Increased recurrence a nd meta stasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells. Int. J. Cancer 74(1), 69-74 (1997).
29. Bonham CA, Lu L, Li Y, Hoffman RA, Simmons RL, Thomson AW. Nitric oxide production by mouse bone marrow-derived dendritic cells: implications for the regulation of allogeneic T cell responses. Transplantation 62(12), 1871-1877 (1996).
30. Della BS, Gennaro M, Vaccari M et al. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br. J. Cancer 89(8), 1463-1472 (2003).
31. Kanto T, Kalinski P, Hunter OC, Lotze MT, Amoscato AA. Ceramide mediates tumor-induced dendritic cell apoptosis. J. Immunol. 167(7), 3773-3784 (2001).
32. Peguet-Navarro J, Sportouch M, Popa I, Berthier O, Schmitt D, Portoukalian J. Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J. Immunol. 170(7), 3488-3494 (2003).
33. Shurin GV, Shurin MR, Bykovskaia S, Shogan J, Lotze MT, Barksdale EM Jr. Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res. 61(1), 363-369 (2001).
34. Sombroek CC, Stam AG, Masterson AJ et al. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J. Immunol. 168(9), 4333-4343 (2002).
35. Yang L, Yamagata N, Yadav R et al. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J. Clin. Invest. 111(5), 727-735 (2003).
36. Yang T, Witham TF, Villa L et al. Glioma-associated hyaluronan induces apoptosis in dendritic cells via inducible nitric oxide synthase: implications for the use of dendritic cells for therapy of gliomas. Cancer Res. 62(9), 2583-2591 (2002).
37. Aalamian M, Tourkova IL, Chatta GS et al. Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen. J. Urol. 170(5), 2026-2030 (2003).
38. Hiltbold EM, Vlad AM, Ciborowski P, Watkins SC, Finn OJ. The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J. Immunol. 165(7), 3730-3741 (2000).
39. Monti P, Leone BE, Zerbi A et al. Tumor-derived MUC1 mucins interact with differentiating monocytes and induce IL-10highIL-12low regulatory dendritic cell. J. Immunol. 172(12), 7341-7349 (2004).
40. Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr. Cancer Drug Targets. 7(1), 31-40 (2007).
41. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 117(5), 1147-1154 (2007).
42. Bukur J, Seliger B. The role of HLA-G for protection of human renal cell-carcinoma cells from immune-mediated lysis: implications for immunotherapies. Semin. Cancer Biol. 13(5), 353-359 (2003).
43. Pistoia V, Morandi F, Wang X, Ferrone S. Soluble HLA-G: are they clinically relevant? Semin. Cancer Biol. 17(6), 469-479 (2007).
44. Hamblin AD, Hamblin TJ. The immunodeficiency of chronic lymphocytic leukaemia. Br-. Med. Bull. 87, 49-62 (2008).
45. Marshall NA, Christie LE, Munro LR et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 103(5), 1755-1762 (2004).
46. van der Velden AM, Claessen AM, van Velzen-Blad H, Biesma DH, Rijkers GT. Development of T cell-mediated immunity after autologous stem cell transplantation: prolonged impairment of antigen-stimulated production of gamma-interferon. Bone Marrow Transplant. 40(3), 261-266 (2007).
47. Couch RB, Englund JA, Whimbey E. Respiratory viral infections in immunocompetent and immunocompromised persons. Am. J. Med. 102(3A), 2-9 (1997).
48. Elting LS, Whimbey E, Lo W, Couch R, Andreeff M, Bodey GP. Epidemiology of influenza A virus infection in patients with acute or chronic leukemia. Support. Care Cancer 3(3), 198-202 (1995).
49. Hassan IA, Chopra R, Swindell R, Mutton KJ. Respiratory viral infections after bone marrow/peripheral stem-cell transplantation: the Christie hospital experience. Bone Marrow Transplant. 32(1), 73-77 (2003).
50. Ljungman P. Respiratory virus infections in bone marrow transplant recipients: the European perspective. Am. J. Med. 102(3A), 44-47 (1997).
51. Ljungman P. Respiratory virus infections in stem cell transplant patients: the European experience. Biol. Blood Marrow Transplant. 7(Suppl.), S5-S7 (2001).
52. Machado CM, Boas LS, Mendes AV et al. Low mortality rates related to respiratory virus infections after bone marrow transplantation. Bone Marrow Transplant. 31(8), 695-700 (2003).
53. Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin. Infect. Dis. 39(9), 1300-1306 (2004).
54. Schepetiuk S, Papanaoum K, Qiao M. Spread of influenza A virus infection in hospitalised patients with cancer. Aust. NZ J. Med. 28(4), 475-476 (1998).
55. Whimbey E, Elting LS, Couch RB et al. Influenza A virus infections among hospitalized adult bone marrow transplant recipients. Bone Marrow Transplant. 13(4), 437-440 (1994).
56. Yousuf HM, Englund J, Couch R et al. Influenza among hospitalized adults with leukemia. Clin. Infect. Dis. 24(6), 1095-1099 (1997).
57. Chemaly RF, Ghosh S, Bodey GP et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 85(5), 278-287 (2006).
58. Taubenberger JK, Morens DM. 1918 Influenza: the mother of all pandemics. Emerg. Infect. Dis. 12(1), 15-22 (2006).
59. Anderson H, Petrie K, Berrisford C, Charlett A, Thatcher N, Zambon M. Seroconversion after influenza vaccination in patients with lung cancer. Br. J. Cancer 80 (1-2), 219-220 (1999).
60. Brydak LB, Guzy J, Starzyk J, Machala M, Gozdz SS. Humoral immune response after vaccination against influenza in patients with breast cancer. Support. Care Cancer 9(1), 65-68 (2001).
61. Ganz PA, Shanley JD, Cherry JD. Responses of patients with neoplastic diseases to influenza virus vaccine. Cancer 42(5), 2244-2247 (1978).
62. Nord0y T, Aaberge IS, Husebekk A et al. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Med. Oncol. 19(2), 71-78 (2002).
63. Ortbals DW, Liebhaber H, Presant CA, Van Amburg AL 3rd, Lee JY. Influenza immunization of adult patients with malignant diseases. Ann. Intern. Med. 87(5), 552-557 (1977).
64. Chisholm J, Howe K, Taj M, Zambon M. Influenza immunisation in children with solid tumours. Eur. J. Cancer 41(15), 2280-2287 (2005).
65. Chisholm JC, Devine T, Charlett A, Pinkerton CR, Zambon M. Response to influenza immunisation during treatment for cancer. Arch. Dis. Child 84(6), 496-500 (2001).
66. Gross PA, Lee H, Wolff JA, Hall CB, Minnefore AB, Lazicki ME. Influenza immunization in immunosuppressed children. J. Pediatr. 92(1), 30-35 (1978).
67. Lange B, Shapiro SA, Waldman MT, Proctor E, Arbeter A. Antibody responses to influenza immunization of children with acute lymphoblastic leukemia. J. Infect. Dis. 140(3), 402-406 (1979). (Pubitemid 10189483)
68. Engelhard D, Nagler A, Hardan I et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant. 11(1), 1-5 (1993).
69. Gandhi MK, Egner W, Sizer L et al. Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients. Bone Marrow Transplant. 28(8), 775-781 (2001).
70. Hodges GR, Davis JW, Lewis HD Jr et al. Response to influenza A vaccine among high-risk patients. South. Med. J. 72(1), 29-32 (1979).
71. Robertson JD, Nagesh K, Jowitt SN et al. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br. J. Cancer 82(7), 1261-1265 (2000).
72. Schafer AI, Churchill WH, Ames P, Weinstein L. The influence of chemotherapy on response of patients with hematologic malignancies to influenza vaccine. Cancer 43(1), 25-30 (1979).
73. Safdar A, Rodriguez GH, Rueda AM et al. Multiple-dose granulocyte-macrophage-colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia: a prospective, randomized trial of safety and immunogenicity. Cancer 113(2), 383-387 (2008).
74. Safdar A, Rodriguez MA, Fayad LE et al. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adu lt patients with non-Hodgkin B cell lymphoma. J. Infect. Dis. 194(10), 1394-1397 (2006).
75. Safdar A, Cox MM. Baculovirus-expressed influenza vaccine. A novel technology for safe and expeditious vaccine production for human use. Expert Opin. Investig. Drugs 16(7), 927-934 (2007).
76. Brown R, Murray A, Pope B et al. Either interleukin-12 or interferon-g can correct the dendritic cell defect induced by transforming growth factor p in patients with myeloma. Br. J. Haematol. 125 (6), 743-748 (2004).
77. Brown RD, Pope B, Murray A et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-p1 and interleukin-10. Blood 98(10), 2992-2998 (2001).
78. Martin-Ayuso M, Almeida J, Perez-Andres M et al. Peripheral blood dendritic cell subsets from patients with monoclonal gammopathies show an abnormal distribution and are functionally impaired. Oncologist 13(1), 82-92 (2008).
79. Orsini E, Guarini A, Chiaretti S, Mauro FR, Foa R. The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response. Cancer Res. 63(15), 4497-4506 (2003).
80. Decker WK, Xing D, Shpall EJ. Dendritic cell immunotherapy for the treatment of neoplastic disease. Biol. Blood Marrow Transplant. 12(2), 113-125 (2006).
81. Ide F, Nakamura T, Tomizawa M et al. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a Phase 1 trial. J. Med. Virol. 78(6), 711-718 (2006).
82. Lu W, Arraes LC, Ferreira WT, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat. Med. 10(12), 1359-1365 (2004).
83. Pett SL. Immunotherapies in HIV-1 infection. Curr. Opin. HIV AIDS4(3), 188-193 (2009).
84. 8+ T cells. J. Clin. Invest. 94(2), 797-807 (1994).
85. Dhodapkar MV, Steinman RM, Sapp M et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J. Clin. Invest. 104(2), 173-180 (1999).
86. Safdar A, Decker WK, Li S et al. De novo T-lymphocyte responses against baculovirus-derived recombinant influenzavirus hemagglutinin generated by a naive umbilical cord blood model of dendritic cell vaccination. Vaccine 27(10), 1479-1484 (2009).
87. Guo G, Chen S, Zhang J et al. Antitumor activity of a fusion of esophageal carcinoma cells with dendritic cells derived from cord blood. Vaccine 23(45), 5225-5230 (2005).
88. Hanley PJ, Cruz CR, Savoldo B et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 114(9), 1958-1967 (2009).
89. Hu Y, He Y, Srivenugopal KS, Fan S, Jiang Y. In vitro antitumor cytotoxic T lymphocyte response induced by dendritic cells transduced with DeltaNp73a recombinant adenovirus. Oncol. Rep. 18(5), 1085-1091 (2007).
90. Osman Y, Narita M, Ayres F et al. Generation of Ag-specific cytotoxic T lymphocytes by DC transfected with in vitro transcribed influenza virus matrix protein (M1) mRNA. Cytotherapy 5(2), 161-168 (2003).
91. Park KD, Marti L, Kurtzberg J, Szabolcs P. In vitro priming and expansion of cytomegalovirus-specific Th1 and Tc1 T cells from naive cord blood lymphocytes. Blood 108(5), 1770-1773 (2006) .
92. Salio M, Dulphy N, Renneson J et al. Efficient priming of antigen-specific cytotoxic T lymphocytes by human cord blood dendritic cells. Int. Immunol. 15(10), 1265-1273 (2003).
93. Wang P, Munger CM, Joshi AD, Pirruccello SJ, Joshi SS. Cytotoxicity of cord blood derived Her2/neu-specific cytotoxic T lymphocytes against human breast cancer in vitro and in vivo. Breast Cancer Res. Treat. 83(1), 15-23 (2004).
94. Rastogi D, Wang C, Mao X, Lendor C, Rothman PB, Miller RL. Antigen-specific immune responses to influenza vaccine in utero. J. Clin. Invest 117(6), 1637-1646 (2007) .
95. Cox RJ, Haaheim LR, Ericsson JC, Madhun AS, Brokstad KA. The humoral and cellular responses induced locally and systemically after parenteral influenza vaccination in man. Vaccine 24(44-46), 6577-6580 (2006).
96. Neff-LaFord HD, Vorderstrasse BA, Lawrence BP. Fewer CTL, not enhanced NK cells, are sufficient for viral clearance from the lungs of immunocompromised mice. Cell Immunol. 226(1), 54-64 (2003).
97. Boon AC, de Mutsert G, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. Functional profile of human influenza virus-specific cytotoxic T lymphocyte activity is influenced by interleukin-2 concentration and epitope specificity. Clin. Exp. Immunol. 142(1), 45-52 (2005).
98. 8+ cytotoxic T lymphocytes. J. Infect. Dis. 180(5), 1477-1486 (1999).
99. Zhang Y, Wang Y, Gilmore X, Xu K, Mbawuike IN. Independent and synergistic effects of interleukin-18 and interleukin-12 in augmenting cytotoxic T lymphocyte responses and IFN-g production in aging. J. Interferon Cytokine Res. 21(10), 843-850 (2001).
100. Decker WK, Xing D, Li S et al. Double loading of dendritic cell MHC class I and MHC class II with an AML antigen repertoire enhances correlates of T-cell immunity in vitro via amplification of T-cell help. Vaccine 24(16), 3203-3216 (2006).
101. Decker WK, Li S, Xing D et al. Deficient T(H)-1 responses from TNF-a-matured and a-CD40-matured dendritic cells. J. Immunother. 31(2), 157-165 (2008).
102. Decker WK, Shpall EJ. Progress in dendritic cell immunotherapy: elucidating the enigma of Th-1 polarization. Hum. Vaccin. 4(2), 162-164 (2008).
103. Decker WK, Xing D, Li S et al. Th-1 polarization is regulated by dendritic-cell comparison of MHC class I and class II antigens. Blood 113(18), 4213-4223 (2009).
104. Ni X, Richmond HM, Liao XM et al. Induction of T-cell responses against cutaneous T-cell lymphomas ex vivo by autologous dendritic cells transfected with amplified tumor mRNA. J. Invest. Dermatol. 128(11), 2631-2639 (2008).
105. Xing D, Decker WK, Li S et al. AML-loaded DC generate Th1-type cellular immune responses in vitro. Cytotherapy 8(2), 95-104 (2006).
106. Ramsay AG, Johnson AJ, Lee AM et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J. Clin. Invest. 118(7), 2427-2437 (2008).
107. Yan XJ, Albesiano E, Zanesi N et al. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 103(31), 11713-11718 (2006).
108. Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, Phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115(16), 3670-3679 (2009).